GHRS Share Price Performance
US$14.00
4.91 (54.02%)
Price US$14.00
Share Pricen/a
We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Aug 27
GH Research PLC Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
GHRS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
GH Research PLC Key Details
About GHRS
- Founded
- 2018
- Employees
- 50
- CEO
- WebsiteView website
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
